Last deal

$12M

Amount

Post-IPO Equity

Stage

19.06.2019

Date

3

all rounds

$75.89M

Total amount

date founded

Financing round

General

About Company
Ampio Pharmaceuticals develops innovative drugs to improve patient care.

Industry

Sector :

Subsector :

founded date

01.01.2011

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company focuses on developing novel therapies for common inflammatory conditions, such as osteoarthritis and respiratory illness. Their lead product, Ampion, is a biologic drug that uses the immune response to address the underlying causes of inflammation. Ampion is being developed for the treatment of severe Osteoarthritis of the Knee, as well as for intravenous and inhaled treatments for COVID-19 patients. Ampio Pharmaceuticals has strong relationships with clinicians, medical centers, and specialized providers, and has a robust portfolio of patents for its products.
Contacts
Similar Companies
999
Adamis Pharmaceuticals

Adamis Pharmaceuticals

Adamis Pharmaceuticals develops and sells specialty pharmaceutical and biotechnology products in different therapeutic areas.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Diego, CA, USA

total rounds

6

total raised

$75.5M

count Of Investments

1
Atrin Pharmaceuticals

Atrin Pharmaceuticals

Atrin Pharmaceuticals is a biopharmaceutical company that is revolutionizing cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Doylestown, PA 18901, USA

total rounds

6

total raised

$1.78M
Abfero Pharmaceuticals

Abfero Pharmaceuticals

Abfero Pharmaceuticals is developing novel therapies for the treatment of iron-overload conditions.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boston, MA, USA

total rounds

4

total raised

$6.68M
ORIC Pharmaceuticals

ORIC Pharmaceuticals

ORIC Pharmaceuticals aims to overcome cancer resistance.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

South San Francisco, CA, USA

total rounds

7

total raised

$408M

Financials

Funding Rounds
3
3

Number of Funding Rounds

$75.89M

Money Raised

Their latest funding was raised on 19.06.2019. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
19.06.2019
$12M
05.03.2014
$63.3M
25.03.2011
$585K
Co-Investors

People

Founders
1
Michael Macaluso
Michael Macaluso

Michael Macaluso

Mr. Macaluso is the Chief Executive Officer, founder and Director of Ampio Pharmaceuticals, Inc. and DMI Life Sciences, Inc. Mr. Macaluso has extensive entrepreneur experience over the past 20 years. He was the founder and principal of International Printing and Publishing managing all phases of its domestic and international commercial printing operations from 1989 until 1997, the owner of Page International Communications, a manufacturing business, from 1998 until 2001, and in 2001 formed Isolagen, Inc, serving as a Director and as President and Chief Executive Officer. Mr. Macaluso is a graduate of Canisius College.

current job

DMI Life Sciences, Inc.
DMI Life Sciences, Inc.

organization founded

2

Michael Macaluso

Employee Profiles
9
Michael A. Martino

Michael A. Martino

Chairman & CEO

Richard B. Giles

Director

Vaughan Clift

Chief Regulatory Affairs Officer

Mark McGregor

CFO

Josh Disbrow

Josh Disbrow

COO

Philip Coelho

Philip Coelho

Director

Michael Macaluso

Michael Macaluso

Founder & CEO

David R. Stevens

Director

Activity

Recent News
4
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month